Back to search
FDAFDA · Food and drugs·Recall number D-0860-2016

LIPO ESCULTURA capsules, 250 mg, 60-count bottles, Distributed By: JAT Productos Naturales Corp., BROOKLYN, NY 11238, www.lipoesculturatreatment.com

Published June 1, 2016 · Recall initiated: December 3, 2015

Summary

FDA records drug Class I recall D-0860-2016, published June 1, 2016 and initiated December 3, 2015. Recalling firm: Lipo Escultura Corp.; Status: Terminated; Reported quantity: unknown; Lot: All lots. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed Without An Approved NDA/ANDA: Tainted product marketed as a dietary supplement. Product found to be tainted with sibutramine, an appetite suppressant that was withdrawn from the U.S. market in October 2010 for safety reasons, and diclofenac, a prescription non-steroidal anti-inflammatory drug, making this an unapproved drug.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Lipo Escultura Corp.
Distributor
Nationwide via Internet sales
Lot
All lots
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was LIPO ESCULTURA capsules, 250 mg, 60-count bottles, Distributed By: JAT Productos Naturales Corp., BROOKLYN, NY 11238, www.lipoesculturatreatment.com recalled?

Yes. FDA published recall D-0860-2016 on June 1, 2016. Reported hazard: Marketed Without An Approved NDA/ANDA: Tainted product marketed as a dietary supplement. Product found to be tainted with sibutramine, an appetite suppressant that was withdrawn from the U.S. market in October 2010 for safety reasons, and diclofenac, a prescription non-steroidal anti-inflammatory drug, making this an unapproved drug.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release